annb0t
Top 20
MGC Pharmaceuticals (ASX:MXC) First Half 2023 Results
Key Financial Results
Revenue: AU$2.66m (up 3.8% from 1H 2022). Net loss: AU$10.9m (loss widened by 46% from 1H 2022). AU$0.004 loss per share (further deteriorated from AU$0.003 loss in 1H 2022). earnings-and-revenue-history
All figures shown in the chart above are for the trailing 12 month (TTM) period
MGC Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared ...
>>> Read more: MGC Pharmaceuticals First Half 2023 Earnings: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)
Key Financial Results
Revenue: AU$2.66m (up 3.8% from 1H 2022). Net loss: AU$10.9m (loss widened by 46% from 1H 2022). AU$0.004 loss per share (further deteriorated from AU$0.003 loss in 1H 2022). earnings-and-revenue-history
All figures shown in the chart above are for the trailing 12 month (TTM) period
MGC Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared ...
>>> Read more: MGC Pharmaceuticals First Half 2023 Earnings: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)
